Hematopoietic Stem Cell Transplantation Efficiency via CD184 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for enhancing hematopoietic stem cell transplantation efficiency are limited by the difficulty in regulating CD184 expression and improving homing ability, which affects the success rate and long-term recovery of patients.
Innovation Solution
The use of specific compounds such as tubulin polymerization inhibitors like Lexibulin, Vinblastine sulfate, and Colchicine to increase CD184 protein expression on the surface of hematopoietic stem cells, enhancing their migration and homing ability to the bone marrow.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods are used to enhance hematopoietic stem cell transplantation efficiency, then transplantation efficiency is limited, but CD184 expression regulation difficulty increases
Solution Approach 1:
The patent uses small molecule compounds to change the expression level of CD184 protein on HSC surface through chemical parameter modulation. This resolves the contradiction by providing a simple chemical parameter control method that directly enhances transplantation efficiency without complex regulatory mechanisms.
2Speed
If CD184 expression is increased to improve homing ability, then migration ability improves, but other HSC functions may be affected
Solution Approach 1:
The patent applies local quality by specifically enhancing CD184 expression on HSC surface while maintaining other cellular functions intact. The small molecule compounds selectively modulate CD184 without affecting other HSC properties, achieving improved migration ability while preserving reliability of other functions.
Solution Approach 2:
The patent uses partial action by selectively targeting only the CD184 expression pathway for enhancement, while leaving other HSC functions at their normal levels. This selective modulation improves migration ability without unnecessarily altering other cellular functions that maintain reliability.
3Productivity
If multiple treatment methods are applied to improve transplantation efficiency, then transplantation efficiency may improve, but operational complexity increases
Solution Approach 1:
The patent merges multiple potential treatment approaches into a single small molecule compound treatment. Instead of applying multiple separate treatments to improve transplantation efficiency, the invention uses one compound that directly enhances CD184 expression, thereby simplifying operational complexity while maintaining improved transplantation efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves the transplantation efficiency and therapeutic effect of hematopoietic stem cells by increasing CD184 expression without affecting cell viability or phenotype, leading to effective repopulation of the hematopoietic system.
Implementation Method 1
The compound is one or more selected from the group consisting of: a tubulin polymerization inhibitor, LND-212854, AZD0364, SCH772984, Pimasertib, Trametinib, IWR-1-endo, TTNPB, JNK-inhibitor IX and CHIR99021
Data Source
AI summary
Provided is the use of a compound for improving the transplantation efficiency of human hematopoietic stem cells, wherein the compound is selected from one of or two or more of a tubulin polymerization inhibitor, LND-212854, AZD0364, SCH772984, Pimasertib, Trametinib, IWR-1-endo, TTNPB, JNK-inhibitor IX and CHIR99021. The compound provided can improve the expression of the hematopoietic stem cell surface protein CD184 by means of in vitro short-time treatment, without affecting the phenotype, survival rate and various characteristics of the cell. By means of the binding of the chemokine receptor CD184 expressed by HSC to the chemokine ligand SDF1 in the bone marrow microenvironment, the migration ability of the HSC and the homing ability thereof in the bone marrow are improved, and the transplantation efficiency and the therapeutic effect of the HSC are enhanced.